Biomarkers: Potential uses and limitations (original) (raw)

Summary

Biomarkers provide a dynamic and powerful approach to understanding the spectrum of neurological disease with applications in observational and analytic epidemiology, randomized clinical trials, screening and diagnosis and prognosis. Defined as alterations in the constituents of tissues or body fluids, these markers offer the means for homogeneous classification of a disease and risk factors, and the can extend our base information about the underlying pathogenesis of disease. Biomarkers can also reflect the entire spectrum of disease from the earliest manifestations to the terminal stages. This brief review describes the major uses of biomarkers in clinical investigation. Careful assessment of the validity of biomarkers is required with respect to the stage of disease. Causes of variability in the measurement of biomarkers range from the individual to the laboratory. Issues that affect the analysis of biomarkers are discussed along with recommendations on how to deal with bias and confounding.

Article PDF

Similar content being viewed by others

References

  1. Hulka BS. Overview of biological markers. In: Biological markers in epidemiology (Hulka BS, Griffith JD, Wilcosky TC, eds), pp 3–15. New York: Oxford University Press, 1990.
    Google Scholar
  2. Naylor S. Biomarkers: current perspectives and future prospects.Expert Rev Mol Diagn 3: 525–529, 2003.
    Article PubMed Google Scholar
  3. Perera FP, Weinstein IB. Molecular epidemiology: recent advances and future directions.Carcinogenesis 21: 517–524, 2000.
    Article PubMed CAS Google Scholar
  4. Gordis L. Epidemiology and public policy. In: Epidemiology (Gordis L, ed), pp 247–256. Philadelphia: W.B. Saunders, 1996.
    Google Scholar
  5. Verbeek MM, De Jong D, Kremer HP. Brain-specific proteins in cerebrospinal fluid for the diagnosis of neurodegenerative diseases.Ann Clin Biochem 40: 25–40, 2003.
    Article PubMed CAS Google Scholar
  6. Galasko D. New approaches to diagnose and treat Alzheimer’s disease: a glimpse of the future.Clin Geriatr Med 17: 393–410, 2001.
    Article PubMed CAS Google Scholar
  7. Rohlff C. Proteomics in neuropsychiatric disorders.Int J Neuropsychopharmacol 4: 93–102, 2001.
    Article PubMed CAS Google Scholar
  8. Reiber H, Peter JB. Cerebrospinal fluid analysis: disease-related data patterns and evaluation programs.J Neurol Sci 184: 101–122, 2001.
    Article PubMed CAS Google Scholar
  9. Schulte PA. A conceptual and historical framework for molecular epidemiology. In: Molecular epidemiology: principles and practices (Schulte PA, Perera FP, eds), pp 3–44. San Diego: Academic Press, 1993.
    Google Scholar
  10. Merikangas K. Genetic epidemiology: bringing genetics to the population—the NAPE Lecture 2001.Acta Psychiatr Scand 105: 3–13, 2002.
    Article PubMed CAS Google Scholar
  11. Muller U, Graeber MB. Neurogenetic diseases: molecular diagnosis and therapeutic approaches.J Mol Med 74: 71–84, 1996.
    Article PubMed CAS Google Scholar
  12. Mayeux R. Epidemiology of neurodegeneration.Annu Rev Neurosci 26: 81–104, 2003.
    Article PubMed CAS Google Scholar
  13. Schulte PA, Perera FP. Validation. In: Molecular epidemiology: principles and practices (Schulte PA, Perera FP, eds), pp 79–107. San Diego: Academic Press, 1993.
    Google Scholar
  14. Pepe MS, Thompson ML. Combining diagnostic test results to increase accuracy.Biostatistics 1: 123–140, 2000.
    Article PubMed Google Scholar
  15. Thompson ML, Zucchini W. On the statistical analysis of ROC curves.Stat Med 8: 1277–1290, 1989.
    Article PubMed CAS Google Scholar
  16. Mayeux R, Saunders AM, Shea S et al. Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer’s disease. Alzheimer’s Disease Centers Consortium on apolipoprotein E and Alzheimer’s disease.N Engl J Med 338: 506–511, 1998.
    Article PubMed CAS Google Scholar

Download references

Author information

Authors and Affiliations

  1. Gertrude H. Sergievsky Center and the Taub Institute for Research on Alzheimer’s Disease and the Aging Brain, College of Physicians and Surgeons, Columbia University, 10032, New York, New York
    Richard Mayeux

Authors

  1. Richard Mayeux
    You can also search for this author inPubMed Google Scholar

Corresponding author

Correspondence toRichard Mayeux.

Rights and permissions

About this article

Cite this article

Mayeux, R. Biomarkers: Potential uses and limitations.Neurotherapeutics 1, 182–188 (2004). https://doi.org/10.1602/neurorx.1.2.182

Download citation

Key Words